Holocene Advisors
REGN icon

Holocene Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Holocene Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-158,300
Closed -$130M – 813
2023
Q3 		$130M Buy
+158,300
New +$124M 0.57% 54
2023
Q2 		– Sell
-149,700
Closed -$123M – 837
2023
Q1 		$123M Buy
+149,700
New +$113M 0.6% 49

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Holocene Advisors's REGN Position: Q1 2026 in Review

Holocene Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 460,723 shares — an estimated $356M sold.

Holocene Advisors first reported a position in REGN in Q4 2017 and held it in 12 quarters. The position peaked at $356M in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Holocene Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Holocene Advisors sold 460,723 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $356M.
  • Holocene Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 12 quarters.
  • Holocene Advisors's Regeneron Pharmaceuticals position peaked at $356M in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.